Christine Thomas - Femasys Senior Affairs
| FEMY Stock | USD 1.01 0.03 3.06% |
Executive
Christine Thomas is Senior Affairs of Femasys
| Age | 51 |
| Address | 3950 Johns Creek Court, Suwanee, GA, United States, 30024 |
| Phone | 770 500 3910 |
| Web | https://www.femasys.com |
Christine Thomas Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christine Thomas against Femasys stock is an integral part of due diligence when investing in Femasys. Christine Thomas insider activity provides valuable insight into whether Femasys is net buyers or sellers over its current business cycle. Note, Femasys insiders must abide by specific rules, including filing SEC forms every time they buy or sell Femasys'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christine Thomas over a year ago Acquisition by Christine Thomas of 60000 shares of Femasys subject to Rule 16b-3 |
Femasys Management Efficiency
The company has return on total asset (ROA) of (0.5954) % which means that it has lost $0.5954 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3837) %, meaning that it created substantial loss on money invested by shareholders. Femasys' management efficiency ratios could be used to measure how well Femasys manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to drop to -0.62 in 2024. At this time, Femasys' Net Tangible Assets are fairly stable compared to the past year. Debt To Assets is likely to rise to 0.18 in 2024, whereas Total Assets are likely to drop slightly above 20.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mark Fox | Utah Medical Products | N/A | |
| Wolfgang Becker | Straumann Holding AG | 57 | |
| Kenneth Miller | Repro Med Systems | 55 | |
| Judy Mazzini | Nephros | N/A | |
| Rob Cannon | Repro Med Systems | N/A | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
| Thomas Adams | Repro Med Systems | 51 | |
| Marcena Clawson | Utah Medical Products | N/A | |
| Addam Chupa | InfuSystems Holdings | 45 | |
| James JD | Milestone Scientific | N/A | |
| Brian Koopman | Utah Medical Products | 54 | |
| Brianne McGuire | Nephros | N/A | |
| Jerod Funke | InfuSystems Holdings | 49 | |
| MS MBA | Nephros | 50 | |
| Mahesh Lawande | Precision Optics, | 51 | |
| Judy CFA | Nephros | 59 | |
| Christopher Pazdan | Repro Med Systems | N/A | |
| Andy Molnar | Milestone Scientific | 62 | |
| Clay Schwabe | Precision Optics, | N/A | |
| Jeffrey DiRubio | Precision Optics, | N/A | |
Management Performance
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.6 |
Femasys Leadership Team
Elected by the shareholders, the Femasys' board of directors comprises two types of representatives: Femasys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Femasys. The board's role is to monitor Femasys' management team and ensure that shareholders' interests are well served. Femasys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Femasys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Damon, VP Devel | ||
| James MD, Chief Officer | ||
| Richard Spector, Chief Officer | ||
| Kathy LeeSepsick, President, Founder | ||
| Christine Thomas, Senior Affairs | ||
| Dov Elefant, Chief Officer | ||
| Todd MBA, Chief Advisor | ||
| Daniel Currie, Senior COO | ||
| MS MD, Chief Advisor | ||
| Kathy MBA, President Founder | ||
| Edward MD, Chief Officer | ||
| Mary JD, Vice Property | ||
| Sue Owens, Vice Sales | ||
| Naomi Phaneuf, Vice Marketing |
Femasys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Femasys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (20.24) % | ||||
| Current Valuation | 22.75 M | ||||
| Shares Outstanding | 22.9 M | ||||
| Shares Owned By Insiders | 7.60 % | ||||
| Shares Owned By Institutions | 7.25 % | ||||
| Number Of Shares Shorted | 526.65 K | ||||
| Price To Earning | 4.67 X | ||||
| Price To Book | 3.87 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Femasys Stock Analysis
When running Femasys' price analysis, check to measure Femasys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Femasys is operating at the current time. Most of Femasys' value examination focuses on studying past and present price action to predict the probability of Femasys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Femasys' price. Additionally, you may evaluate how the addition of Femasys to your portfolios can decrease your overall portfolio volatility.